May 28, 2025 10:00 AM EDTUpdated 11:24 AM
Pharma
In Focus

A new dawn for psy­che­delics? Com­pass could be the first to find out

Ayisha Sharma

News Reporter

The sum­mer of 2024 was a dark time for psy­che­delics.

The sec­tor was reel­ing af­ter Lykos Ther­a­peu­tics failed to se­cure FDA ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times